Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cameron

Showing results (461-470 of 481) with videos related to

Pageof 49
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrantLuca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
The New England Journal of Medicine|December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerRashmi K Murthy, Sherene Loi, Alicia Okines, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Lancet (London, England)|February 18, 2014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Lijun Zhang, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)Erica L Mayer, Christian Fesl, Dominik Hlauschek, et al.
Breast (Edinburgh, Scotland)|February 13, 2025
An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42Vesna Bjelic-Radisic, Fatima Cardoso, Joachim Weis, et al.
NPJ Breast Cancer|May 11, 2026
Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2)Yara Abdou, Mariya Rozenblit, Dario Trapani, et al.
The New England Journal of Medicine|November 5, 2025
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast CancerIan H Kunkler, Nicola S Russell, Niall Anderson, et al.
Cancer|July 10, 2024
Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendationsHesham Elghazaly, Hamdy A Azim, Hope S Rugo, et al.
Pageof 49

Showing results (461-470 of 481) with videos related to

Sort By:
Pageof 49
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrantLuca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
The New England Journal of Medicine|December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerRashmi K Murthy, Sherene Loi, Alicia Okines, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Lancet (London, England)|February 18, 2014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Lijun Zhang, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)Erica L Mayer, Christian Fesl, Dominik Hlauschek, et al.
Breast (Edinburgh, Scotland)|February 13, 2025
An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42Vesna Bjelic-Radisic, Fatima Cardoso, Joachim Weis, et al.
NPJ Breast Cancer|May 11, 2026
Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2)Yara Abdou, Mariya Rozenblit, Dario Trapani, et al.
The New England Journal of Medicine|November 5, 2025
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast CancerIan H Kunkler, Nicola S Russell, Niall Anderson, et al.
Cancer|July 10, 2024
Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendationsHesham Elghazaly, Hamdy A Azim, Hope S Rugo, et al.
Pageof 49